Clinical characteristics and prognostic analysis of multiple primary malignant neoplasms in female patients with breast cancer or genitalia malignancies

Abstract

Background As public awareness of health has increased and diagnostic and treatment options have improved, the survival of patients with malignant tumors has continued to extend, and the population has been aging, the number of multiple primary malignant neoplasms has gradually increased in recent years. There are few reports concerning female patients with multiple primary malignant neoplasms of breast cancer or genitalia malignancies. In this study, we aimed to analyze the clinical characteristics and prognosis of multiple primary malignant neoplasms in female patients with breast cancer or genitalia malignancies, as well as further explore the factors that affect the survival. Methods We collected clinical data on 80 female patients diagnosed with multiple primary malignant neoplasms of the breast or genitalia, described their clinical features. Furthermore, we calculated the survival and prognostic factors for 52 participants. Results In our study, the prevalence rate of multiple primary malignant neoplasms was 0.66% (367/55404). Corresponding to female patients with multiple primary malignant neoplasms of breast cancer or genitalia malignancies, it was 1.4% (80/5707). the median age of diagnosis for the first tumor was 48 years, and the median age of diagnosis for the second tumor was 52 years. Regarding the interval, 67.57% (50/74) of patients were within five years. Most tumors were located in the breast (44.68%), followed by the uterus (20.21%), the ovary (17.02%), and the cervix (15.96%). The overall 12-, 36-and 60-month survival rates of the patients were 86.4%, 74.3%, and 69.8%. For the female patients, the stage (III–IV) (P = 0.046), non-radical surgery (P = 0.002), and types of the last tumor (breast cancer or genitalia malignancies) (P = 0.019) were associated with the poor prognosis. Conclusions Female patients with breast cancer or genital malignancies should pay attention to screening for the second tumor, especially within 4 years after the first tumor diagnosed. Furthermore, during tumor screening, it may be recommended for these patients to focus on colorectal cancer and lung cancer. Compared with previous studies, in addition to clinical staging and types of surgery, we found whether the last tumor was breast cancer or genitalia malignancies should also be considered a prognostic factor.

Analysis and prediction of second primary malignancy in patients with breast cancer

“…The results of the present study indicated that 9.32% of patients with BC developed SPMs within 7 years after the diagnosis of the primary malignancy and that this proportion would keep increasing if the follow-up were to be continued. This finding is similar to the results of Xiao et al (16).…”

“…Although a small number of studies have looked into whether menopausal women are more likely to develop SPMs, the present study found that patients with SPMs were mostly HER2 -/HR + menopausal patients with a median age of 63 years, consistent with the finding of Xiao et al (16) that >70% of the patients had reached menopause prior to the diagnosis of the SPMs. Therefore, it may be reasonable to suggest that SPM monitoring should begin after the end of the BC regimen.…”

“…Therefore, the risk of developing SPMs gradually increases with age (17,18). In addition, compared with the general population, cancer patients have a much higher risk of developing SPMs (16). The results of the present study indicated that 9.32% of patients with BC developed SPMs within 7 years after the diagnosis of the primary malignancy and that this proportion would keep increasing if the follow-up were to be continued.…”

“…Most studies have indicated that the clinical factors influencing the survival of patients with BC include tumor stage, estrogen receptor status, progesterone receptor status and HER2 status (15). However, with the aging of the population and the continuous extension of the survival time of patients with BC, the incidence rate of multiple primary malignancies has gradually increased in recent years (16). The OS of patients with BC is related to not only the primary malignancy but also the nature of SPMs and the organs bearing the SPMs.…”

Genetic Analysis of Multiple Primary Malignant Tumors in Women with Breast and Ovarian Cancer

“…So, the mean age of first (52.7 years) and even second (58.7 years) neoplasms in the group was lower than the age of cancer manifestation in Russia (63.9 years for women in 2019). The same trend is noted by other authors [ 25 , 26 ]. The mean age of BC for the first and subsequent tumors (64 malignancies, 56.1 years) is lower than the average in Russia (61.0 years).…”